Company news
Oric Pharmaceuticals, Inc. news in 2022
Oric Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer
December 20, 2022
ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting
December 12, 2022
ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 7, 2022
ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update
November 6, 2022
ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting
November 2, 2022
ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
August 10, 2022
ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 1, 2022
ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022
ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update
May 8, 2022
ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting
April 11, 2022
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update
March 20, 2022
ORIC Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Update Conference Call
March 16, 2022
ORIC Pharmaceuticals Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
March 7, 2022
ORIC Pharmaceuticals to Participate in the Guggenheim 2022 Oncology Conference
February 1, 2022
ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications
January 24, 2022
ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Calls in 2022
Decks in 2022
- FY2021 Earnings Presentation
Earnings · 15 slides · Mar 21, 2022